Since porcine gelatin is utilised as a stabiliser to maintain the safety and efficacy of vaccines during storage, rising demand for gelatin is anticipated to drive the market's expansion. Additionally, worries about the increased prevalence of zoonotic illnesses and the growing demand for meat, milk, eggs, and animal protein are anticipated to fuel the expansion of the porcine vaccines market throughout the course of the projected period. The market for pig vaccines is also being driven by an increase in the number of biotechnology firms, research institutions working on the production of porcine vaccines, and government financing programmes for the agriculture and animal husbandry sectors.
At a CAGR of 7.50% over the forecast period (2023-2028), the size of the global porcine vaccine market is anticipated to increase from USD 1,908.49 million in 2023 to USD 2,739.89 million by 2028.
Major Players in the Porcine Vaccines Industry:
Bayer AG:
1. Established in 1863. German headquarters are in Leverkusen. A healthcare and agricultural conglomerate from Germany is called Bayer. Health care, which includes pharmaceutical medications, vitamins, and other consumer healthcare products, accounts for about half of the business's sales. With the addition of Monsanto, the company's crop science division, which already comprises seeds, insecticides, herbicides, and fungicides, has grown. Bayer announces in March that it has sold its Environmental Science Professional division to the global private equity firm Cinven. In Bayer's efforts to optimise its portfolio, the transaction's completion in October marks a significant turning point. There will be a 2.6 billion dollar purchasing price.
Boehringer Ingelheim GmbH:
2. Created in 1969. Headquarters in Rhein/Ingelheim, Germany. Boehringer Ingelheim Pharmaceuticals' Rosemer Operations. The business offers standard and client-specific polymers for use in pharmaceutical formulations and medical applications.10 brands of pharmaceuticals. Brands like Antistax®, Bisolvon®, Buscopan®, Dulcolax®, Eve®, Mucoangin®, Mucosolvan®, Pharmaton®, Thomapyrin®, and Zantac® are among those offered by the Consumer Health Care division. These medications work effectively for treating colds and coughs, sore throats, generalised discomfort, gastrointestinal issues, and deficiencies in vitamins and minerals that are essential for both physical and mental health. Today, NBE-Therapeutics, a private, clinical-stage Swiss Biotechnology Company focused on antibody-drug conjugates and advancing targeted cancer medicines derived from its immune stimulatory iADCTM platform, announced the signing of a legally binding agreement for Boehringer Ingelheim to acquire all of its outstanding shares.
Ceva Sante Animale:
3. Established in 1999. Headquarters at France's Libourne. Animal companion and farm animal producing animals are the target market for the manufacturer of veterinary pharmaceutical goods. The business provides goods for cardiology, swine and ruminant behaviour and locomotion, antibiotic therapy and reproduction control, poultry vaccines and vaccination equipment, pharmaceuticals, and disinfectants, ultimately assisting health authorities in safeguarding the health of both humans and animals. The Argentinian businesses Zoovet, which specialises in the development and marketing of animal health products, and Biotecnofe, a biotech start-up creating novel products to be sold by Zoovet, have been acquired by Ceva Santé Animale (Ceva).